Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07373782

Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer

This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer. CPAP is a device commonly used to support breathing, for example in patients with sleep apnea. The investigators expect a reduction in radiation doses to the heart and/or lungs with CPAP-supported radiotherapy compared to standard radiotherapy (without CPAP), which may also lead to a decrease in radiation-induced heart and/or lung conditions in the long term. The study will also examine how the use of a CPAP device can be implemented in daily radiotherapy practice.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

About this study

Patients undergoing breast conserving surgery for invasive or in situ BC and requiring adjuvant RT are prospectively enrolled -either left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with continuous positive airway pressure (CPAP) (15cm H20) -in free breathing (FB) for right-sided cases and in deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH are evaluated in FB. Two RT plans (with and without CPAP) are dosimetrically compared. If CPAP reduces mean heart or CLB dose by ≥0.5 Gy, or mean lung dose by ≥1 Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • At least 40 years of age and 80 years or younger at the time of signing the Informed Consent Form (ICF)
  • Female patients
  • Patients that underwent breast conserving surgery (BCS)
  • Left-sided invasive BC / in situ carcinoma with indication for adjuvant RT (<70 years old)
  • Left-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes) (70-80 years old)
  • Right-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes)
  • Prior chemotherapy allowed
  • Prior immunotherapy allowed
  • Prior / concomitant hormonal therapy allowed
  • Prior / concomitant HER2-targeted therapy allowed

Exclusion criteria

  • Patient has active bullous lung disease, bypassed upper airway, pneumothorax, cerebral spinal fluid leaks, abnormalities of the cribriform plate (contra-indications for the use of CPAP)
  • Patient has history of major head trauma and/or pneumocephalus (contra-indications for the use of CPAP)
  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.
  • Female who is pregnant, breast-feeding or intends to become pregnant (which is a contra-indication for RT in general)
  • Male BC patients
  • Patients that underwent mastectomy Patients whose initial tumor was located just beneath the skin (defined as being less than 28mm below the breast surface), indicating the need for an electron boost
  • Patients requiring RT boost on positive lymph nodes
  • Distant metastasis
  • Breast implants in situ
  • Right-sided in situ carcinoma
  • Right-sided invasive BC only requiring local adjuvant RT (without irradiation of the regional lymph nodes, because the presumed benefit on cardiac doses of local right-sided breast irradiation is assumed to be rather small because of the left anatomical position of the heart)
  • Bilateral BC
  • Concomitant use of chemotherapy during RT
  • Substantial comorbidities, incompatible with RT or CPAP use, estimated by the treating radiation oncologist
  • Insufficient arm mobility to perform comfortable arm positioning in radiation treatment position, evaluated by the treating radiation oncologist
  • Other active oncological disease / treatment with the exception of non-melanoma skin cancer
  • Previous RT with overlapping RT fields with actual target volume

Treatment and study plan

Continuous Positive Airway Pressure (CPAP)

Device

Positive airway pressure (15cmH2O) delivered by a CPAP-device

Primary outcomes

  1. Mean heart dose

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Potential change of mean radiation dose to the heart

Secondary outcomes

  1. Doses to cardiac substructures

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Potential change in radiation dose to cardiac substructures

  2. Mean lung dose

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Potential change in mean radiation dose to the lungs

  3. Mean contralateral breast dose

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Potential change in mean radiation dose to the contralateral breast

  4. Liver dose

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Potential change in radiation dose to the liver

  5. Patient comfort

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Patient comfort assessed through patient questionnaires (Likert scale: Strongly disagree - disagree - neutral - agree - strongly agree)

  6. Reproducibility and accuracy of CPAP-assisted radiotherapy

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    Compare reproducibility and accuracy between standard and CPAP-assisted RT by using surface scanning and daily cone beam CT (CBCT) parameters

  7. DIBH performance

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    To compare DIBH performance between standard and CPAP-assisted RT for left-sided BC by using surface scanning and daily CBCT parameters

  8. Time-effectiveness

    Time frame: From enrollment to the end of treatment at +/-8 weeks

    To compare time-effectiveness between standard and CPAP-assisted RT

    • Set-up time
    • Matching time
    • Radiation time

Study contacts

Contact information is provided by the study sponsor or research team.

Aline Van der Vorst, MD

CONTACT

[email protected]

+3216340115

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Collaborators

  • VitalAire

Registry information

Official study title

Reducing Cardiac Radiation Dose in Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer: a Prospective Non-Randomized Clinical Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jan 28, 2026
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.